PeterDavidByeffMD

Oncology • Southington, CT

Breast Cancer, Gastrointestinal Cancer, Head & Neck Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Byeff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Byeff's full profile

Already have an account?

Office
55 Meriden Ave
Ste 1A
Southington, CT 06489
Phone+1 860-621-9316

Fax+1 860-620-5526

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1981
MedStar Georgetown University Hospital1977
MedStar Health/Georgetown University HospitalInternship, Internal Medicine, 1974 - 1975
Johns Hopkins University School of MedicineClass of 1974

Certifications & Licensure

NY State Medical License 1977 - Present
CT State Medical License 1982 - 2025
FL State Medical License 1982 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Connecticut Top Doctor Connecticut Magazine, 2021-2022
Johns Hopkins University Heritage Award Johns Hopkins School of Medicine, 2015
Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Nov 01
Unknown status
Phase 2
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Start of enrollment: 2008 Oct 07
Completed
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Start of enrollment: 2014 Aug 06
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

10 citations
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethas...
Katja Weisel, Meletios A. Dimopoulos, Philippe Moreau, Münci Yağcı, Alessandra Larocca
Leukemia & Lymphoma. 2020-04-09
56 citations
Mycobacterium haemophilum Infection in Immunocompromised Patients: Case Report and Review of the Literature
Mar Kristjansson, Virginia M. Bieluch, Peter D. Byeff
Reviews of Infectious Diseases. 1991-09-01
19 citations
Phenotypic heterogeneity of human T-cell malignancies: Demonstration by monoclonal antibodies and cytochemical markers
Daniel M. Knowles, James P. Halper, Genevieve A. Machin, Peter Byeff, Roland Mertelsman
American Journal of Hematology. 1982-05-01

Lectures

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bor...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member